HeyJaredMatt Gamber’s Biotech Newsletter
Weekly posts on small and mid-cap biotech stocks. 100% independent and reader supported with no company sponsored content or hedge fund compensation of any kind. See free performance posts for more information. Not financial advice, for research purposes.
- Indexed issues, last 90 days
- 8
- Latest publication
- Sep 21, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 6, 2026
Latest issues
My Key Takeaways From Conference Season (opens the original)
Read excerpt
Word Count: 11,390 words, Reading Time: 56 minutes. Not financial advice, do your own due diligence, for entertainment purposes only.Subscribers: Substack is telling me this post is too long for email so please load in browser if the bottom cuts off before my signature.Today I am going to focus on conference presentations over the last two weeks from seven companies I’m following closely.The companies are:
A Quick Note On The Breaking Cullinan News (opens the original)
Read excerpt
Hi everyone! There is breaking news with Cullinan so I wanted to put out a rare Sunday night time-sensitive news post real quickly with my thoughts before the company’s webinar early Monday morning. Read more
One Piece Of Good News And One Piece Of Bad News For Geron (opens the original)
Read excerpt
Word Count: 1,995 words, Reading Time: 10 minutes. Not financial advice, do your own due diligence, for entertainment purposes only.Subscribers: Substack is telling me this post is too long for email so please load in browser if the bottom cuts off before my signature.Hi everyone,This is a shorter article this week but no less important.Last week I tried out a fun new feature for Cullinan highlighting one piece of news that made me a little more bearish about the company and one piece of news th
One Piece Of Good News And One Piece Of Bad News For Cullinan (opens the original)
Read excerpt
Word Count: 3,035 words, Reading Time: 15 minutes. Not financial advice, do your own due diligence, for entertainment purposes only.Subscribers: Substack is telling me this post is too long for email so please load in browser if the bottom cuts off before my signature.I just wrote my last piece about Cullinan one month ago but multiple new material pieces of information have now come out post earnings release which makes another article a necessity. All but one of the new items is positive and e
Q2 2026 Earnings Review (opens the original)
Read excerpt
Word Count: 6,201 words, Reading Time: 30 minutes. Not financial advice, do your own due diligence, for entertainment purposes only.Subscribers: Substack is telling me this post is too long for email so please load in browser if the bottom cuts off before my signature.Okay with nearly all the companies I follow done reporting earnings it’s time to get into who raised their stock (figuratively, literally) and who lowered it.I’m way too busy to write a long intro so let’s just get started!TGTX -</
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.